Wize Pharma
Wize Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders.
Wize Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders.
Wize Pharma is a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders. The company has in-licensed certain rights to purchase, market, sell, and distribute a formula known as LO2A, which is currently registered and marketed in Germany, Switzerland, Hungary, and the Netherlands for the treatment of Dry Eye Syndrome (DES), CCh, and Sjögren's syndrome (Sjögren's). Founded in 1982, Wize is based in Israel and recently received a $7.50M Post-IPO Equity investment on 19 February 2020. The company has completed a Phase II trial of LO2A for patients with CCh and is currently conducting a Phase IV study for LO2A for DES in patients with Sjögren's. Wize's strategy involves engaging local or multinational distributors to handle the distribution of LO2A. As a promising player in the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries, Wize Pharma presents an exciting investment opportunity with its innovative approach to addressing ophthalmic disorders.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $7.50M | - | 19 Feb 2020 |
No recent news or press coverage available for Wize Pharma .
We care about your data, and we'd love to use cookies make your experience better.
